{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:48:16Z","timestamp":1791823696194,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10072-026-09466-7","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:09:56Z","timestamp":1791774596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation pharmacological strategies for Parkinson\u2019s disease: a systematic literature review of symptom management and disease modification"],"prefix":"10.1007","volume":"47","author":[{"given":"Rajan","family":"Rajabalaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul Kiruba N.","family":"Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Chellappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Philip","family":"Kunnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-0873","authenticated-orcid":false,"given":"Jestin","family":"Chellian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"1","key":"9466_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00207454.2018.1486837","volume":"129","author":"AU Khan","year":"2019","unstructured":"Khan AU, Akram M, Daniyal M, Zainab R (2019) Awareness and current knowledge of Parkinson\u2019s disease: a neurodegenerative disorder. Int J Neurosci 129(1):55\u201393","journal-title":"Int J Neurosci"},{"issue":"1","key":"9466_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.37349\/ent.2023.00036","volume":"3","author":"K Radad","year":"2023","unstructured":"Radad K, Moldzio R, Krewenka C, Kranner B, Rausch WD (2023) Pathophysiology of non-motor signs in Parkinson\u2019s disease: some recent updating with brief presentation. Explor Neuroprotect Ther 3(1):24\u201346","journal-title":"Explor Neuroprotect Ther"},{"key":"9466_CR3","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Zelayeta L, Delgado-Minjares K, Rojas MV, Le\u00f3n-Arcia K, Santiago-Balmaseda A, Andrade-Guerrero J et al (2025) Non-motor symptoms in Parkinson\u2019s disease","DOI":"10.20944\/preprints202503.1395.v1"},{"key":"9466_CR4","unstructured":"Rinaldi D (2025) Motor and non-motor symptoms in advanced Parkinson\u2019s disease: current insights and future directions"},{"issue":"1","key":"9466_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JPD-202323","volume":"11","author":"Y Compta","year":"2021","unstructured":"Compta Y, Revesz T (2021) Neuropathological and biomarker findings in Parkinson\u2019s disease and Alzheimer\u2019s disease: from protein aggregates to synaptic dysfunction. J Parkinsons Dis 11(1):107\u2013121","journal-title":"J Parkinsons Dis"},{"key":"9466_CR6","doi-asserted-by":"publisher","first-page":"971252","DOI":"10.3389\/fneur.2022.971252","volume":"13","author":"LJ Smith","year":"2022","unstructured":"Smith LJ, Lee CY, Menozzi E, Schapira AH (2022) Genetic variations in GBA1 and LRRK2 genes: biochemical and clinical consequences in Parkinson disease. Front Neurol 13:971252","journal-title":"Front Neurol"},{"issue":"13","key":"9466_CR7","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/ijms25137183","volume":"25","author":"M Muleiro Alvarez","year":"2024","unstructured":"Muleiro Alvarez M, Cano-Herrera G, Osorio Martinez MF, Vega Gonzales-Portillo J, Monroy GR, Murguiondo Perez R et al (2024) A comprehensive approach to Parkinson\u2019s disease: addressing its molecular, clinical, and therapeutic aspects. Int J Mol Sci 25(13):7183","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9466_CR8","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/brain\/awaa181","volume":"143","author":"R Cilia","year":"2020","unstructured":"Cilia R, Cereda E, Akpalu A, Sarfo FS, Cham M, Laryea R et al (2020) Natural history of motor symptoms in Parkinson\u2019s disease and the long-duration response to levodopa. Brain 143(8):2490\u20132501","journal-title":"Brain"},{"issue":"5","key":"9466_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/pharmaceutics15051503","volume":"15","author":"DD Nakmode","year":"2023","unstructured":"Nakmode DD, Day CM, Song Y, Garg S (2023) The management of Parkinson\u2019s disease: an overview of the current advancements in drug delivery systems. Pharmaceutics 15(5):1503","journal-title":"Pharmaceutics"},{"issue":"1","key":"9466_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","volume":"12","author":"ZD Zhou","year":"2023","unstructured":"Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK (2023) Role of dopamine in the pathophysiology of Parkinson\u2019s disease. Transl Neurodegener 12(1):44","journal-title":"Transl Neurodegener"},{"key":"9466_CR11","doi-asserted-by":"crossref","unstructured":"Menozzi E, Schapira AH, Borghammer P (2025) The gut-brain axis in Parkinson disease: emerging concepts and therapeutic implications. Mov Disord Clin Pract","DOI":"10.1002\/mdc3.70029"},{"issue":"1","key":"9466_CR12","doi-asserted-by":"publisher","first-page":"25051","DOI":"10.1038\/s41598-024-76941-6","volume":"14","author":"M Oh","year":"2024","unstructured":"Oh M, Kim H, Lee HK (2024) Medication recommendation for Parkinson\u2019s disease based on dynamics of symptom progression. Sci Rep 14(1):25051","journal-title":"Sci Rep"},{"key":"9466_CR13","first-page":"6635618","volume":"2021","author":"JA Szasz","year":"2021","unstructured":"Szasz JA, Jianu DC, Simu MA, Constantin VA, Dulamea AO, Onuk K et al (2021) Characterizing advanced Parkinson\u2019s disease: Romanian subanalysis from the OBSERVE-PD study. Parkinsons Dis 2021:6635618","journal-title":"Parkinsons Dis"},{"key":"9466_CR14","doi-asserted-by":"crossref","unstructured":"Baradari E, Akan OB (2024) Molecular communication-based intelligent dopamine rate modulator for Parkinson\u2019s disease treatment. IEEE Trans Nanobiosci","DOI":"10.1109\/TNB.2024.3456031"},{"issue":"8","key":"9466_CR15","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/brain\/awz176","volume":"142","author":"C Rosenblad","year":"2019","unstructured":"Rosenblad C, Li Q, Pioli EY, Dovero S, Antunes AS, Ag\u00fandez L et al (2019) Vector-mediated L-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson\u2019s disease. Brain 142(8):2402\u20132416","journal-title":"Brain"},{"issue":"2","key":"9466_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/JPD-191576","volume":"9","author":"AL Whone","year":"2019","unstructured":"Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S et al (2019) Extended treatment with glial cell line-derived neurotrophic factor in Parkinson\u2019s disease. J Parkinsons Dis 9(2):301\u2013313","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"9466_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","volume":"78","author":"CW Olanow","year":"2015","unstructured":"Olanow CW, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M et al (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78(2):248\u2013257","journal-title":"Ann Neurol"},{"issue":"5","key":"9466_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mds.27993","volume":"35","author":"JG Nutt","year":"2020","unstructured":"Nutt JG, Curtze C, Hiller A, Anderson S, Larson PS, Van Laar AD et al (2020) Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson\u2019s disease. Mov Disord 35(5):851\u2013858","journal-title":"Mov Disord"},{"issue":"11","key":"9466_CR19","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"B Kantor","year":"2018","unstructured":"Kantor B, Tagliafierro L, Gu J, Zamora ME, Ilich E, Grenier C et al (2018) Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD. Mol Ther 26(11):2638\u20132649","journal-title":"Mol Ther"},{"issue":"1","key":"9466_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/crispr.2021.0025","volume":"5","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Ye S, Lim S, Jo A, Lee H, Hong F et al (2022) CRISPR-Cas9 gene editing protects from A53T-SNCA overexpression-induced pathology of Parkinson\u2019s disease in vivo. CRISPR J 5(1):95\u2013108","journal-title":"CRISPR J"},{"issue":"4","key":"9466_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ejn.14286","volume":"49","author":"Y Chen","year":"2019","unstructured":"Chen Y, Dolt KS, Kriek M, Baker T, Downey P, Drummond NJ et al (2019) Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. Eur J Neurosci 49(4):510\u2013524","journal-title":"Eur J Neurosci"},{"key":"9466_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fncel.2015.00097","volume":"9","author":"M Acquarone","year":"2015","unstructured":"Acquarone M, de Melo TM, Meireles F, Brito-Moreira J, Oliveira G, Ferreira ST et al (2015) Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson\u2019s disease. Front Cell Neurosci 9:97","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"9466_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.stem.2016.03.014","volume":"18","author":"Y Chen","year":"2016","unstructured":"Chen Y, Xiong M, Dong Y, Haberman A, Cao J, Liu H et al (2016) Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson\u2019s disease. Cell Stem Cell 18(6):817\u2013826","journal-title":"Cell Stem Cell"},{"issue":"5","key":"9466_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker RA, Parmar M, Studer L, Takahashi J (2017) Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era. Cell Stem Cell 21(5):569\u2013573","journal-title":"Cell Stem Cell"},{"issue":"10","key":"9466_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby A, Nelander J, Hoban DB, Rogelius N, Bjartmarz H, Storm P et al (2023) Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30(10):1299\u20131314","journal-title":"Cell Stem Cell"},{"issue":"5","key":"9466_CR26","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1021\/nn506408v","volume":"9","author":"R Pahuja","year":"2015","unstructured":"Pahuja R, Seth K, Shukla A, Shukla RK, Bhatnagar P, Chauhan LKS et al (2015) Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 9(5):4850\u20134871","journal-title":"ACS Nano"},{"issue":"1","key":"9466_CR27","doi-asserted-by":"publisher","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","volume":"11","author":"V Monge-Fuentes","year":"2021","unstructured":"Monge-Fuentes V, Biolchi Mayer A, Lima MR, Geraldes LR, Zanotto LN, Moreira KG et al (2021) Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s disease. Sci Rep 11(1):15185","journal-title":"Sci Rep"},{"issue":"1","key":"9466_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","volume":"26","author":"S Tang","year":"2019","unstructured":"Tang S, Wang A, Yan X, Chu L, Yang X, Song Y et al (2019) Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease. Drug Deliv 26(1):700\u2013707","journal-title":"Drug Deliv"},{"issue":"20","key":"9466_CR29","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1039\/D1TB00481F","volume":"9","author":"V Morales","year":"2021","unstructured":"Morales V, McConnell J, P\u00e9rez-Garnes M, Almendro N, Sanz R, Garc\u00eda-Mu\u00f1oz RA (2021) L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson\u2019s disease. J Mater Chem B 9(20):4178\u20134189","journal-title":"J Mater Chem B"},{"issue":"19","key":"9466_CR30","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.3390\/ma12193202","volume":"12","author":"S Swar","year":"2019","unstructured":"Swar S, M\u00e1kov\u00e1 V, Stibor I (2019) Effectiveness of diverse mesoporous silica nanoparticles as potent vehicles for the drug L-DOPA. Materials 12(19):3202","journal-title":"Materials"},{"issue":"2","key":"9466_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/nano10020235","volume":"10","author":"R Ruotolo","year":"2020","unstructured":"Ruotolo R, De Giorgio G, Minato I, Bianchi MG, Bussolati O, Marmiroli N (2020) Cerium oxide nanoparticles rescue \u03b1-synuclein-induced toxicity in a yeast model of Parkinson\u2019s disease. Nanomaterials 10(2):235","journal-title":"Nanomaterials"},{"key":"9466_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu W, Jalewa J, Sharma M, Li G, Li L, H\u00f6lscher C (2015) Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson\u2019s disease. Neuroscience 303:42\u201350","journal-title":"Neuroscience"},{"issue":"1","key":"9466_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang L, Li L, H\u00f6lscher C (2019) Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis 9(1):157\u2013171","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"9466_CR34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AH (2016) Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann Neurol 80(5):766\u2013775","journal-title":"Ann Neurol"},{"issue":"4","key":"9466_CR35","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J et al (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol 77(4):427\u2013434","journal-title":"JAMA Neurol"},{"issue":"1","key":"9466_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL et al (2017) The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun 5(1):53","journal-title":"Acta Neuropathol Commun"},{"key":"9466_CR37","first-page":"251213724","volume":"arXiv","author":"A Noori","year":"2025","unstructured":"Noori A, Polonuer J, Meyer K, Budnik B, Morton S, Wang X et al (2025) Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems. arXiv arXiv:251213724","journal-title":"arXiv"},{"key":"9466_CR38","unstructured":"Kim JS, Jeong C, Kim S, Kim H, Lee S, Jo KB et al (2026) Deep plasma proteomics coupled with functional genomics reveals drivers of Parkinson\u2019s disease progression and levodopa response. bioRxiv"},{"key":"9466_CR39","doi-asserted-by":"crossref","unstructured":"Ding L, Xiao Y, Xu Z, Zhu Z, Gan T, Huang X et al (2026) RVG-targeted extracellular vesicles loaded with echinatin attenuate dopaminergic neurodegeneration via the IGF-2\/PI3K\/Akt pathway in Parkinson\u2019s disease mice. J Nanobiotechnol","DOI":"10.1186\/s12951-025-03997-5"},{"key":"9466_CR40","doi-asserted-by":"publisher","first-page":"1596139","DOI":"10.3389\/fphar.2025.1596139","volume":"16","author":"A Hayashi","year":"2025","unstructured":"Hayashi A, Hosomi A, Kihara S, Nishi M, Torisawa S, Ouchi Y et al (2025) A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics. Front Pharmacol 16:1596139","journal-title":"Front Pharmacol"},{"key":"9466_CR41","doi-asserted-by":"crossref","unstructured":"Yu C, Liu W, Gong A, Ye M, Huang H, Zhao Y, Liu C, Guo Y, Chen J, Zhang X, Chen X et al (2025) Levodopa\/carbidopa\/entacapone versus levodopa\/benserazide plus pramipexole in Chinese patients with Parkinson\u2019s disease experiencing wearing off. Front Neurol 16:1682614.","DOI":"10.3389\/fneur.2025.1682614"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09466-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:02:56Z","timestamp":1791820976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09466-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9466"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09466-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"852"}}